| Filed On | Filing |
|---|---|
| 12 May 2023 |
8-K/A: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities
On March 30, 2023, Vitro Biopharma, Inc. (the “Company”) entered into definitive agreements with two accredited investors for the sale of an aggregate of $350,000 of 8% convertible promissory notes (“Convertible Notes”) and warrants to p... |
| 12 May 2023 |
8-K/A: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities
On March 15, 2023, Vitro Biopharma, Inc. (the “Company”) entered into definitive agreements with accredited investors for the sale of an aggregate of $237,600 of 8% convertible promissory notes (“Convertible Notes”) and warrants to purch... |
| 04 Feb 2020 | 8-K/A: Results of Operations and Financial Condition; Unregistered Sales of Equity Securities +2 more |
| 28 Jun 2011 | 8-K/A: Entry into a Material Definitive Agreement; Other Events |
| 24 Jan 2007 | 8-K/A: Changes in Registrant's Certifying Accountant |
| 11 Jan 2006 | 8-K/A: Changes in Registrant's Certifying Accountant |
| 02 Nov 2000 | 8-K/A: Changes in Registrant's Certifying Accountant |
| 23 Oct 1996 | 8-K/A: Changes in Registrant's Certifying Accountant |
Loading...
